STOCK TITAN
  1. Home
  2. Sec-filings
  3. NTLA
  4. [8-K] Intellia Therapeutics, Inc. Reports Material Event

Intellia Therapeutics (NTLA) posts 2026 shareholder voting results

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Intellia Therapeutics, Inc. reported the results of its Annual Meeting of stockholders held on June 9, 2026. Stockholders voted on three proposals that had been described in the company’s Proxy Statement.

For the election of directors, Muna Bhanji received 57,065,465 votes for and 1,610,941 against, Brian Goff received 46,090,644 for and 12,582,130 against, and Jesse Goodman received 43,004,221 for and 15,686,289 against, each with additional abstentions and 30,124,178 broker non-votes. A separate proposal received 87,833,534 votes for, 779,540 against, and 249,592 abstentions, with no broker non-votes. Another proposal received 44,806,637 votes for, 13,821,404 against, 110,447 abstentions, and 30,124,178 broker non-votes. No other matters were submitted to stockholders.

Positive

  • None.

Negative

  • None.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Votes for Muna Bhanji 57,065,465 votes Director election at June 9, 2026 Annual Meeting
Votes for Brian Goff 46,090,644 votes Director election at June 9, 2026 Annual Meeting
Votes for Jesse Goodman 43,004,221 votes Director election at June 9, 2026 Annual Meeting
Broker non-votes for director items 30,124,178 votes Broker non-votes recorded for each director election
Votes for second proposal 87,833,534 votes Second proposal at June 9, 2026 Annual Meeting
Votes against second proposal 779,540 votes Second proposal at June 9, 2026 Annual Meeting
Votes for third proposal 44,806,637 votes Third proposal at June 9, 2026 Annual Meeting
Votes against third proposal 13,821,404 votes Third proposal at June 9, 2026 Annual Meeting
Annual Meeting financial
"On June 9, 2026, Intellia Therapeutics, Inc. held its Annual Meeting"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
Proxy Statement financial
"each of which is described in detail in the Proxy Statement"
A proxy statement is a document companies send to shareholders ahead of a meeting that lays out the items up for a vote—like who will sit on the board, executive pay, and major corporate decisions—and provides background so shareholders can decide how to cast their votes or appoint someone to vote for them. Think of it as an agenda plus a ballot and briefing notes, important because the outcomes can change control, strategy, and value.
Broker Non-Votes financial
"Votes For, Against, Abstain, Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
Submission of Matters to a Vote of Security Holders financial
"Item 5.07 Submission of Matters to a Vote of Security Holders"
Emerging growth company regulatory
"Emerging growth company check box language in the header section"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
false000165213000016521302026-06-092026-06-09

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 09, 2026

 

 

INTELLIA THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-37766

36-4785571

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

40 Erie Street, Suite 130

 

Cambridge, Massachusetts

 

02139

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 857 285-6200

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

NTLA

 

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 9, 2026, Intellia Therapeutics, Inc. (the "Company") held its Annual Meeting to consider and vote on the three proposals set forth below, each of which is described in detail in the Proxy Statement. The following is a summary of the matters voted on at the Annual Meeting.

 

a)

The stockholders of the Company elected each of Muna Bhanji, R.Ph., Brian Goff and Jesse Goodman, M.D., M.P.H., as a class I director, for a three-year term ending at the annual meeting of stockholders to be held in 2029 and until his or her successor has been duly elected and qualified or until his or her earlier resignation or removal. The results of the stockholders’ vote with respect to the election of the class I directors were as follows:

 

 

 

Votes

 

 

Votes

 

 

 

 

 

Broker

 

Name

 

For

 

 

Against

 

 

Abstain

 

 

Non-Votes

 

Muna Bhanji, R.Ph.

 

 

57,065,465

 

 

 

1,610,941

 

 

 

62,082

 

 

 

30,124,178

 

Brian Goff

 

 

46,090,644

 

 

 

12,582,130

 

 

 

65,714

 

 

 

30,124,178

 

Jesse Goodman, M.D., M.P.H.

 

 

43,004,221

 

 

 

15,686,289

 

 

 

47,978

 

 

 

30,124,178

 

 

b)

The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the stockholders’ vote with respect to such ratification were as follows:

Votes

 

 

Votes

 

 

 

 

 

Broker

 

For

 

 

Against

 

 

Abstain

 

 

Non-Votes

 

 

87,833,534

 

 

 

779,540

 

 

 

249,592

 

 

 

-

 

 

c)

The stockholders of the Company approved, on a non-binding advisory basis, the compensation of our named executive officers. The results of the stockholders’ vote with respect to the approval of the compensation of our named executive officers were as follows:

 

Votes

 

 

Votes

 

 

 

 

 

Broker

 

For

 

 

Against

 

 

Abstain

 

 

Non-Votes

 

 

44,806,637

 

 

 

13,821,404

 

 

 

110,447

 

 

 

30,124,178

 

 

No other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Intellia Therapeutics, Inc.

Date: June 10, 2026

 

By:

/s/ John M. Leonard

Name: John M. Leonard

Title: Chief Executive Officer and President

 

Source: View Original Filing on SEC EDGAR

FAQ

What did Intellia Therapeutics (NTLA) disclose in this 8-K filing?

Intellia Therapeutics disclosed the detailed voting results from its June 9, 2026 Annual Meeting. Stockholders voted on three proposals described in the Proxy Statement, including director elections and two additional items, with full tallies of for, against, abstain, and broker non-votes.

How did Intellia Therapeutics (NTLA) stockholders vote on director elections?

Stockholders cast separate votes for three directors. Muna Bhanji received 57,065,465 votes for, Brian Goff 46,090,644 for, and Jesse Goodman 43,004,221 for, each with millions of votes against, some abstentions, and 30,124,178 broker non-votes recorded for each director.

What were the overall vote totals for Intellia Therapeutics’ second proposal?

The second proposal received 87,833,534 votes for, 779,540 against, and 249,592 abstentions, with no broker non-votes. These results indicate very strong support among voting stockholders for this item, which was previously described in the company’s Proxy Statement.

How did Intellia Therapeutics stockholders vote on the third proposal?

The third proposal received 44,806,637 votes for, 13,821,404 against, and 110,447 abstentions, along with 30,124,178 broker non-votes. This breakdown shows a clear majority of votes cast in favor, alongside a sizable number of shares not voted due to broker non-votes.

Were any other matters considered at Intellia Therapeutics’ 2026 Annual Meeting?

No. The company stated that no other matters were submitted to or voted on by stockholders at the Annual Meeting. Only the three proposals described in the Proxy Statement—director elections and two additional items—were presented for stockholder consideration.

Where were Intellia Therapeutics’ annual meeting proposals described in detail?

The company noted that each of the three proposals voted on at the Annual Meeting was described in detail in its Proxy Statement. That document provided full background, terms, and rationale for the director elections and the two additional stockholder proposals.

Filing Exhibits & Attachments

1 document

Other Documents